Authors


Morgan Bayer

Latest:

Maintaining Docetaxel Dose Intensity in mHSPC with G-CSF in ARASENS Regimen

Phase 3 ARASENS trial results highlight the role of G-CSF in optimizing docetaxel delivery within the darolutamide-based regimen for mHSPC.


Ali H. Zaidi, MD

Latest:

Lung Cancer Home Health Screening Tools May Aid in Triaging LDCT+ Patients

The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.


Kasey Bamel, NP

Latest:

Assessing Treatment Options for ALK+ NSCLC

This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.



Rebecca Previs, MD

Latest:

Emerging Front-Line Maintenance Therapies for Advanced Ovarian Cancer

Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.



Coral Omene, MD, PhD

Latest:

Best Practices for Boosting the Enrollment of Underserved Populations in Cancer Clinical Trials

Coral Omene, MD, PhD, and Mariam Eskander, MD, MPH, discuss how to continue engagement in clinical trial enrollment for underserved populations.


ONCOLOGY Staff

Latest:

3 Things You Should Know About Adverse Events With Targeted Therapies for DLBCL

Tips from experts on how to think about and manage adverse events in patients with diffuse large B-cell lymphoma.






Pooja Advani, MBBS, MD

Latest:

Future Perspectives in the Treatment of Chronic Lymphocytic Leukemia

Concluding their discussion, Drs Advani, Parrondo, and Chanan-Khan conclude that second-generation BTK inhibitors are the preferred first-line treatment in patients with chronic lymphocytic leukemia due to better efficacy and lower cardiovascular risk, with emerging therapies promising even better outcomes.



Rakhshanda Rahman, MD, FRCS, FACS

Latest:

Expert Discusses Screening Advocacy, AI, and Developments in Breast Cancer

Early screening for breast cancer may help match patients with appropriate systemic therapies depending on the extent of their tumors, according to Rakhshanda Rahman, MD, FRCS, FACS.


Amulya Yellala, MD

Latest:

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.



Kerolos Rizk, MD

Latest:

Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma

This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.




Michał Kostrzanowski, MD

Latest:

Extreme Case of Surgical Port Metastasis in Ovarian Cancer

We present the case of a 51-year-old woman with metastatic International FIGO stage IIIC ovarian cancer who had delayed her therapy after initial laparoscopy due to COVID-19 infection and presented with an extreme case of surgical port metastasis.


Axel Bex, MD, PhD

Latest:

‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says Expert

Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.



Gregory Cooper, MD

Latest:

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.


Miguel A. Álvarez-Avitia, MD

Latest:

Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma

This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.


Tu My To, PhD, MPH

Latest:

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.



Edmund Qiao

Latest:

Key Presentations at ASCO 2021 Review Primary Prevention of Prostate Cancer in African American Men

CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.


Kebede Begna, MD

Latest:

Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical Progression

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.


Joaquim Bellmunt, MD, PhD

Latest:

Extending the Benefits of Avelumab Maintenance in Urothelial Carcinoma

Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.